Synergistic antitumor activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways

Pharmazie

Volumn 70, Issue 2, 2015, Pages 117-122

  Guo, Li Shu ^a   Li, Hong Xia ^a   Li, Chun Yang ^a   Zhang, Sheng Yan ^a   Chen, Jia ^a   Wang, Qi Long ^a   Gao, Jing Miao ^a   Liang, Jia Qi ^a   Gao, Ming Tang ^a   Wu, Yong Jie ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; COLECALCIFEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; P70S6K PROTEIN; PHOSPHOTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN S6; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; VITAMIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; MTT ASSAY; ONCOGENE C MYC; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLECALCIFEROL; DRUG SYNERGISM; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TOR SERINE-THREONINE KINASES; VITAMINS;

EID: 84927649403     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2015.4535     Document Type: Article

References (17)

1. Bost F, Ben-Sahra I, Tanti JF (2012) Prevention of mutagenesis: new potential mechanisms of metformin action in neoplastic cells. Cancer Prev Res 5: 503-506.
2. Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK, Malone JM (1991) Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res 51: 2848-2853.
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434.
4. Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signaling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7: 684-700.
5. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG (2007) Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117:2638-2648.
6. Harris TE, Lawrence JC Jr (2003) TOR signaling. Sci STKE 2003: re15.
7. Jiralerspong S, Gonzalez-Angulo AM, Hung MC (2009) Expanding the arsenal: Metformin for the treatment of triple-negative breast cancer. Cell Cycle 8: 2031-2040.
8. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69: 6539-6545.
9. Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD (2011) Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of ErbB2/IGF-1 receptor interactions. Cell Cycle 10: 2959-2966.
10. Ma Y, Yu WD, Trump DL, Johnson CS (2010) 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 116: 3294-3303.
11. Nizamutdinova IT, Lee GW, Son KH, Jeon SJ, Kang SS, Kim YS, Lee JH, Seo HG, Chang KC, Kim HJ (2008) Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int J Onc 33: 485-491.
12. Perez EA, Patel T, Moreno-Aspitia A (2010) Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 121: 261-271.
13. Shackelford DB, Shaw RJ (2009) The LKB1-AMPK pathway: metabolism and growth control in tumor suppression. Nat Rev Cancer 9: 563-575.
14. Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I, Werner H (2013) Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One 8: e61537.
15. Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537.
16. Xiong Y, Lu QJ, Zhao J, Wu GY (2012) Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. Asian Pac J Cancer Prev 13: 3275-3279.
17. Yu WD, Ma Y, Flynn G, Muindi JR, Kong RX, Trump DL, Johnson CS (2010) Calcitriol enhances gemcitabine antitumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle 9: 3022-3029.